Excellos, Cell Therapy Contract And Development Manufacturing Organization Member Of Blood Centers Of America Has Been Selected To Manufacture Galapagos' Car-t Cell Therapy Candidate, GLPG5101, For Its Recently FDA-Cleared ATALANTA-1 Study For...
Excellos, Cell Therapy Contract And Development Manufacturing Organization Member Of Blood Centers Of America Has Been Selected To Manufacture Galapagos' Car-t Cell Therapy Candidate, GLPG5101, For Its Recently FDA-Cleared ATALANTA-1 Study For...
Excellos, 電芯療法合同和開發製造組織，美國血液中心成員，已被選中爲製造galapagos的CAR-T細胞療法候選藥物GLPG5101，用於其最近獲得FDA批准的ATALANTA-1研究項目...
Excellos, Cell Therapy Contract And Development Manufacturing Organization Member Of Blood Centers Of America Has Been Selected To Manufacture Galapagos' Car-t Cell Therapy Candidate, GLPG5101, For Its Recently FDA-Cleared ATALANTA-1 Study For Relapsed/Refractory Non-Hodgkin Lymphoma
Excellos，血液中心製造業-半導體合同和開發製造組織成員已被選中製造galapagos公司的CAR-T電芯療法候選藥GLPG5101，用於其最近獲得FDA批准的ATALANTA-1研究項目，用於復發/難治非霍奇金淋巴瘤
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。